Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor

Journal of Medicinal Chemistry

Volumn 55, Issue 2, 2012, Pages 956-960

  Long, Alexander ^a   Zhao, Huilin ^a   Huang, Xin ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IDELTA; CASEIN KINASE IEPSILON; ENZYME INHIBITOR; PF 670462; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME INHIBITOR INTERACTION; ENZYME STRUCTURE; HUMAN; HYDROGEN BOND;

AMINO ACID SEQUENCE; APOENZYMES; CASEIN KINASE IDELTA; CASEIN KINASE IEPSILON; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863065424     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201387s     Document Type: Article

References (25)

1. Vielhaber, E.; Virshup, D. M. Casein kinase I: from obscurity to center stage IUBMB Life 2001, 51 (2) 73-78 (Pubitemid 32651761)
2. Knippschild, U.; Gocht, A.; Wolff, S.; Huber, N.; Lohler, J.; Stoter, M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes Cell. Signalling 2005, 17 (6) 675-689 (Pubitemid 40250168)
3. Price, M. A. CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling Genes Dev. 2006, 20 (4) 399-410
4. Virshup, D. M.; Eide, E. J.; Forger, D. B.; Gallego, M.; Harnish, E. V. Reversible protein phosphorylation regulates circadian rhythms Cold Spring Harbor Symp. Quant. Biol. 2007, 72, 413-420
5. Eide, E. J.; Vielhaber, E. L.; Hinz, W. A.; Virshup, D. M. The circadian regulatory proteins BMAL1 and cryptochromes are substrates of casein kinase I epsilon J. Biol. Chem. 2002, 277 (19) 17248-17254 (Pubitemid 34967759)
6. Eide, E. J.; Woolf, M. F.; Kang, H.; Woolf, P.; Hurst, W.; Camacho, F.; Vielhaber, E. L.; Giovanni, A.; Virshup, D. M. Control of mammalian circadian rhythm by CKI epsilon-regulated proteasome-mediated PER2 degradation Mol. Cell. Biol. 2005, 25 (7) 2795-2807 (Pubitemid 40381641)
7. Xu, Y.; Padiath, Q. S.; Shapiro, R. E.; Jones, C. R.; Wu, S. C.; Saigoh, N.; Saigoh, K.; Ptacek, L. J.; Fu, Y.-H. Functional consequences of a CKI delta mutation causing familial advanced sleep phase syndrome Nature 2005, 434 (7033) 640-644 (Pubitemid 40488555)
8. Grueneberg, D. A.; Degot, S.; Pearlberg, J.; Li, W.; Davies, J. E.; Baldwin, A.; Endege, W.; Doench, J.; Sawyer, J.; Hu, Y.; Boyce, F.; Xian, J.; Munger, K.; Harlow, E. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (43) 16472-16477
9. Yang, W. S.; Stockwell, B. R. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest Genome Biol. 2008, 9 (6) R92
10. Brockschmidt, C.; Hirner, H.; Huber, N.; Eismann, T.; Hillenbrand, A.; Giamas, G.; Radunsky, B.; Ammerpohl, O.; Bohm, B.; Henne-Bruns, D.; Kalthoff, H.; Leithauser, F.; Trauzold, A.; Knippschild, U. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo Gut 2008, 57 (6) 799-806 (Pubitemid 351716974)
11. Li, D.; Herrera, S.; Bubula, N.; Nikitina, E.; Palmer, A. A.; Hanck, D. A.; Loweth, J. A.; Vezina, P. Casein kinase 1 enables nucleus accumbens amphetamine-induced locomotion by regulating AMPA receptor phosphorylation J. Neurochem. 2011, 118 (2) 237-247
12. Badura, L.; Swanson, T.; Adamowicz, W.; Adams, J.; Cianfrogna, J.; Fisher, K.; Holland, J.; Kleiman, R.; Nelson, F.; Reynolds, L.; St. Germain, K.; Schaeffer, E.; Tate, B.; Sprouse, J. An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions J. Pharmacol. Exp. Ther. 2007, 322 (2) 730-738 (Pubitemid 47105782)
13. Walton, K. M.; Fisher, K.; Rubitski, D.; Marconi, M.; Meng, Q.-J.; Sladek, M.; Adams, J.; Bass, M.; Chandrasekaran, R.; Butler, T.; Griffor, M.; Rajamohan, F.; Serpa, M.; Chen, Y.; Claffey, M.; Hastings, M.; Loudon, A.; Maywood, E.; Ohren, J.; Doran, A.; Wager, T. T. Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period J. Pharmacol. Exp. Ther. 2009, 330 (2) 430-439
14. Sprouse, J.; Reynolds, L.; Kleiman, R.; Tate, B.; Swanson, T. A.; Pickard, G. E. Chronic treatment with a selective inhibitor of casein kinase I delta/epsilon yields cumulative phase delays in circadian rhythms Psychopharmacology (Berlin, Ger.) 2010, 210 (4) 569-576
15. Meng, Q.-J.; Maywood, E. S.; Bechtold, D. A.; Lu, W.-Q.; Li, J.; Gibbs, J. E.; Dupre, S. M.; Chesham, J. E.; Rajamohan, F.; Knafels, J.; Sneed, B.; Zawadzke, L. E.; Ohren, J. F.; Walton, K. M.; Wager, T. T.; Hastings, M. H.; Loudon, A. S. I. Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (34) 15240-15245
16. Cheong, J. K.; Nguyen, T. H.; Wang, H.; Tan, P.; Voorhoeve, P. M.; Lee, S. H.; Virshup, D. M. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1delta/epsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation Oncogene 2011, 30 (22) 2558-69
17. Longenecker, K. L.; Roach, P. J.; Hurley, T. D. Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition J. Mol. Biol. 1996, 257 (3) 618-631 (Pubitemid 26107226)
18. Longenecker, K. L.; Roach, P. J.; Hurley, T. D. Crystallographic studies of casein kinase I delta toward a structural understanding of auto-inhibition Acta Crystallogr. D Biol. Crystallogr. 1998, 54 (Pt 3) 473-475
19. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298 (5600) 1912-1934 (Pubitemid 35425239)
20. Aertgeerts, K.; Skene, R.; Yano, J.; Sang, B.-C.; Zou, H.; Snell, G.; Jennings, A.; Iwamoto, K.; Habuka, N.; Hirokawa, A.; Ishikawa, T.; Tanaka, T.; Miki, H.; Ohta, Y.; Sogabe, S. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein J. Biol. Chem. 2011, 286 (21) 18756-18765
21. Fidanze, S. D.; Erickson, S. A.; Wang, G. T.; Mantei, R.; Clark, R. F.; Sorensen, B. K.; Bamaung, N. Y.; Kovar, P.; Johnson, E. F.; Swinger, K. K.; Stewart, K. D.; Zhang, Q.; Tucker, L. A.; Pappano, W. N.; Wilsbacher, J. L.; Wang, J.; Sheppard, G. S.; Bell, R. L.; Davidsen, S. K.; Hubbard, R. D. Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases Bioorg. Med. Chem. Lett. 2010, 20 (8) 2452-2455
22. Xu, G.; Searle, L. L.; Hughes, T. V.; Beck, A. K.; Connolly, P. J.; Abad, M. C.; Neeper, M. P.; Struble, G. T.; Springer, B. A.; Emanuel, S. L.; Gruninger, R. H.; Pandey, N.; Adams, M.; Moreno-Mazza, S.; Fuentes-Pesquera, A. R.; Middleton, S. A.; Greenberger, L. M. Discovery of novel 4-amino-6- arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases Bioorg. Med. Chem. Lett. 2008, 18 (12) 3495-3499 (Pubitemid 351790731)
23. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 2004, 64 (18) 6652-6659 (Pubitemid 39297926)
24. Tamayo, N.; Liao, L.; Goldberg, M.; Powers, D.; Tudor, Y.-Y.; Yu, V.; Wong, L. M.; Henkle, B.; Middleton, S.; Syed, R.; Harvey, T.; Jang, G.; Hungate, R.; Dominguez, C. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase Bioorg. Med. Chem. Lett. 2005, 15 (9) 2409-2413 (Pubitemid 40523109)
25. Martin, M. W.; Newcomb, J.; Nunes, J. J.; McGowan, D. C.; Armistead, D. M.; Boucher, C.; Buchanan, J. L.; Buckner, W.; Chai, L.; Elbaum, D.; Epstein, L. F.; Faust, T.; Flynn, S.; Gallant, P.; Gore, A.; Gu, Y.; Hsieh, F.; Huang, X.; Lee, J. H.; Metz, D.; Middleton, S.; Mohn, D.; Morgenstern, K.; Morrison, M. J.; Novak, P. M.; Oliveira-dos-Santos, A.; Powers, D.; Rose, P.; Schneider, S.; Sell, S.; Tudor, Y.; Turci, S. M.; Welcher, A. A.; White, R. D.; Zack, D.; Zhao, H.; Zhu, L.; Zhu, X.; Ghiron, C.; Amouzegh, P.; Ermann, M.; Jenkins, J.; Johnston, D.; Napier, S.; Power, E. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity J. Med. Chem. 2006, 49 (16) 4981-4991 (Pubitemid 44201056)